Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US)
Zeidan A, Wang R, Davidoff A, Gore S, Soulos P, Huntington S, Gross C, Ma X. Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US). Blood 2015, 126: 873. DOI: 10.1182/blood.v126.23.873.873.Peer-Reviewed Original ResearchDisability Status ScoreOverall survivalMyelodysplastic syndromeMDS patientsCost of careStudy cohortLack of associationHistologic subtypeStatus scoreMedicare beneficiariesEnd Results-Medicare databaseProportional hazards regression modelsOverall study cohortMedian overall survivalOutcomes of patientsElixhauser comorbidity scoreDate of diagnosisEntire study cohortKaplan-Meier methodHazards regression modelsDisease-related costsNon-white raceEnd of studyDate of deathMedicare Part AMyelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study
Wang R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study. Blood 2015, 126: 3295. DOI: 10.1182/blood.v126.23.3295.3295.Peer-Reviewed Original ResearchMDS/AMLProstate cancer patientsIntensity-modulated radiotherapyProstate cancer diagnosisImpact of radiotherapyCancer patientsMyelodysplastic syndromeProstate cancerMyeloid malignanciesSecond malignanciesHazard ratioCancer diagnosisRadiation modalitiesEnd Results-Medicare databaseElderly prostate cancer patientsRisk of MDSMultivariate modelRetrospective cohort studyRole of radiotherapyElixhauser comorbidity scoreAcute myeloid leukemia diagnosisHistory of anemiaAcute myeloid leukemiaEnd of studyExternal beam radiotherapyComparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Zeidan A, Long J, Hall J, Wang R, Huntington S, Abel G, Prebet T, Podoltsev N, Gross C, Gore S, Ma X, Davidoff A. Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). Blood 2015, 126: 3285. DOI: 10.1182/blood.v126.23.3285.3285.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeHR-MDS patientsKaplan-Meier survival curvesEnd of studyHMA initiationMedian OSClinical trialsComorbidity countHazard ratioHigh school educationClinical practiceMultivariate Cox proportional hazards modelSurvival curvesEnd Results-Medicare databaseMedian household incomeRandomized phase III trialReal-world clinical practiceCox proportional hazards modelOlder MDS patientsDisability Status ScoreRetrospective cohort studyOverall survival advantagePhase III trialsYear of diagnosisErythropoiesis-stimulating agents